Biomarkers of cartilage turnover and joint metabolism have a potential use in detecting early degenerative changes after a traumatic knee joint injury; however, no study has analyzed biomarkers before an anterior cruciate ligament (ACL) injury and again after injury or in comparison with a similar group of uninjured controls.
Hypothesis:
Changes in serum biomarker levels and the ratio of cartilage degradation to synthesis, from baseline to follow-up, would be significantly different between ACL-injured patients and uninjured controls.
Study Design:
Case-control study; Level of evidence, 3.
Methods:
This case-control study was conducted to examine changes in serum biomarkers of cartilage turnover following ACL injury in a young athletic population. Specifically, 2 markers for type II collagen and aggrecan synthesis (CPII and CS846, respectively) and 2 markers of types I and II degradation and type II degradation only (C1,2C and C2C, respectively) were studied. Preinjury baseline serum samples and postinjury follow-up samples were obtained for 45 ACL-injured cases and 45 uninjured controls matched for sex, age, height, and weight.
Results:
Results revealed significant decreases in C1,2C (P = .042) and C2C (P = .006) over time in the ACL-injured group when compared with the controls. The change in serum concentrations of CS846 from baseline to follow-up was also significantly different between the ACL-injured patients and uninjured controls (P = .002), as was the change between groups in the ratio of C2C:CPII over time (P = .013). No preinjury differences in the ratio of C1,2C:CPII or C2C:CPII were observed between groups; however, postinjury differences were observed for both ratios.
Conclusion:
Changes in biomarker concentrations after an ACL injury suggest an alteration in cartilage turnover and joint metabolism in those sustaining ACL injuries compared with uninjured matched controls.
Armed Forces Health Surveillance Center. Guidelines for collecting, maintaining, requesting, and using specimens stored in the Department of Defense Serum Repository. Army Medical Surveillance Activity, Directorate of Epidemiology and Disease Surveillance, US Army Center for Health Promotion and Preventive Medicine. May29, 2003. Available at: http://www.afhsc.mil/viewDocument?file=DoDSR_Items/110615_IPM2011-05RequestsPHP.pdf. Accessed June 19, 2013.
BauerDCHunterDJAbramsonSB. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage. 2006;14(8):723-727.
4.
BillinghurstRCDahlbergLIonescuM. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest. 1997;99(7):1534-1545.
5.
BirminghamJDVilimVKrausVB. Collagen biomarkers for arthritis applications. Biomarker Insights. 2006;1:61-76.
6.
BodenBPSheehanFTTorgJSHewettTE. Noncontact anterior cruciate ligament injuries: mechanisms and risk factors. J Am Acad Orthop Surg. 2010;18(9):520-527.
7.
BrownTDJohnstonRCSaltzmanCLMarshJLBuckwalterJA. Posttraumatic osteoarthritis: a first estimate of incidence, prevalence, and burden of disease. J Orthop Trauma. 2006;20(10):739-744.
8.
BuckwalterJALaneNE. Athletics and osteoarthritis. Am J Sports Med. 1997;25(6):873-881.
9.
BuckwalterJAMankinHJ. Articular cartilage II: degeneration and osteoarthrosis, repair, regeneration, and transplantation. J Bone Joint Surg Am. 1997;79:612-632.
10.
CahueSSharmaLDunlopD. The ratio of type II collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritis. Osteoarthritis Cartilage. 2007;15(7):819-823.
11.
CatterallJBStablerTVFlanneryCRKrausVB. Changes in serum and synovial fluid biomarkers after acute injury (NCT00332254). Arthritis Res Ther. 2010;12(6):R229.
12.
CibereJZhangHGarneroP. Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. Arthritis Rheum. 2009;60(5):1372-1380.
13.
DavisMAEttingerWHNeuhausJMChoSAHauckWW. The association of knee injury and obesity with unilateral and bilateral osteoarthritis of the knee. Am J Epidemiol. 1989;130(2):278-288.
14.
FelsonDTLawrenceRCDieppePA. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med. 2000;133(8):635-646.
15.
GarneroPAyralXRousseauJC. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum. 2002;46(10):2613-2624.
16.
GelberACHochbergMCMeadLAWangNYWigleyFMKlagMJ. Joint injury in young adults and risk for subsequent knee and hip osteoarthritis. Ann Intern Med. 2000;133(5):321-328.
17.
GlantTTMikeczKRoughleyPJBuzasEPooleAR. Age-related changes in protein-related epitopes of human articular-cartilage proteoglycans. Biochem J. 1986;236(1):71-75.
18.
GoldringMB. The role of the chondrocyte in osteoarthritis. Arthritis Rheum. 2000;43(9):1916-1926.
19.
HochbergMC. Epidemiology of osteoarthritis: current concepts and new insights. J Rheumatol Suppl. 1991;27:4-6.
HunterDJLiJLaValleyM. Cartilage markers and their association with cartilage loss on magnetic resonance imaging in knee osteoarthritis: the Boston Osteoarthritis Knee Study. Arthritis Res Ther. 2007;9(5):R108.
22.
JonesJCBurksROwensBDSturdivantRXSvobodaSJCameronKL. Incidence and risk factors associated with meniscal injuries among active-duty US military service members. J Athl Train. 2012;47(1):67-73.
23.
KongSYStablerTVCriscioneLGElliottALJordanJMKrausVB. Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. Arthritis Rheum. 2006;54(8):2496-2504.
24.
KrausVB. Osteoarthritis year 2010 in review: biochemical markers. Osteoarthritis Cartilage. 2011;19(4):346-353.
25.
KrausVB. Waiting for action on the osteoarthritis front. Curr Drug Targets. 2010;11(5):518-520.
26.
KrausVBBurnettBCoindreauJ. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage. 2011;19(5):515-542.
27.
KrausVBNevittMSandellLJ. Summary of the OA Biomarkers Workshop 2009—biochemical biomarkers: biology, validation, and clinical studies. Osteoarthritis Cartilage. 2010;18(6):742-745.
28.
LohmanderLSEnglundPMDahlLLRoosEM. The long-term consequence of anterior cruciate ligament and meniscus injuries: osteoarthritis. Am J Sports Med. 2007;35(10):1756-1769.
29.
LohmanderLSIonescuMJugessurHPooleAR. Changes in joint cartilage aggrecan after knee injury and in osteoarthritis. Arthritis Rheum. 1999;42(3):534-544.
30.
LohmanderLSOstenbergAEnglundMRoosH. High prevalence of knee osteoarthritis, pain, and functional limitations in female soccer players twelve years after anterior cruciate ligament injury. Arthritis Rheum. 2004;50(10):3145-3152.
31.
MeulenbeltIKrausVBSandellLJLoughlinJ. Summary of the OA Biomarkers Workshop 2010—genetics and genomics: new targets in OA. Osteoarthritis Cartilage. 2011;19(9):1091-1094.
32.
MountcastleSBPosnerMKraghJFJrTaylorDC. Gender differences in anterior cruciate ligament injury vary with activity: epidemiology of anterior cruciate ligament injuries in a young, athletic population. Am J Sports Med. 2007;35(10):1635-1642.
33.
NelsonFDahlbergLLavertyS. Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J Clin Invest. 1998;102(12):2115-2125.
34.
NiyibiziCWuJJEyreDR. The carboxypropeptide trimer of type II collagen is a prominent component of immature cartilages and intervertebral-disc tissue. Biochim Biophys Acta. 1987;916(3):493-499.
35.
OlivieroFRamondaRPunziL. New horizons in osteoarthritis. Swiss Med Wkly. 2010;140:w13098.
36.
OwensBDMountcastleSBDunnWRDeBerardinoTMTaylorDC. Incidence of anterior cruciate ligament injury among active duty U.S. military servicemen and servicewomen. Mil Med. 2007;172(1):90-91.
37.
PooleAR. Biochemical/immunochemical biomarkers of osteoarthritis: utility for prediction of incident or progressive osteoarthritis. Rheum Dis Clin North Am. 2003;29(4):803-818.
38.
PooleARIonescuMFitzcharlesMABillinghurstRC. The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. J Immunological Methods. 2004;294:145-153.
39.
PooleARIonescuMSwanADieppePA. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan: implications for pathogenesis. J Clin Invest. 1994;94(1):25-33.
40.
RizkallaGReinerABogochEPooleAR. Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis: evidence for molecular heterogeneity and extensive molecular changes in disease. J Clin Invest. 1992;90(6):2268-2277.
41.
RubertoneMVBrundageJF. The Defense Medical Surveillance System and the Department of Defense Serum Repository: glimpses of the future of public health surveillance. Am J Public Health. 2002;92(12):1900-1904.
42.
SzkloMNietoFJ. Stratification and adjustment: multivariate analysis in epidemiology. In: Epidemiology Beyond the Basics. 2nd ed.Salisbury, Massachusetts: Jones and Bartlett; 2007:227-295.
43.
TaylorDCDeBerardinoTMNelsonBJ. Patellar tendon versus hamstring tendon autografts for anterior cruciate ligament reconstruction: a randomized controlled trial using similar femoral and tibial fixation methods. Am J Sports Med. 2009;37(10):1946-1957.
44.
ToivanenATHeliovaaraMImpivaaraO. Obesity, physically demanding work and traumatic knee injury are major risk factors for knee osteoarthritis: a population-based study with a follow-up of 22 years. Rheumatology (Oxford). 2010;49(2):308-314.
45.
van SpilWEDeGrootJLemsWFOostveenJCLafeberFP. Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. Osteoarthritis Cartilage. 2010;18(5):605-612.
46.
WilderFVHallBJBarrettJPJrLemrowNB. History of acute knee injury and osteoarthritis of the knee: a prospective epidemiological assessment. The Clearwater Osteoarthritis Study. Osteoarthritis Cartilage. 2002;10(8):611-616.
